Treatment of Osteoporosis: Unmet Needs and Emerging Solutions.
10.11005/jbm.2018.25.3.133
- Author:
Bente Lomholt LANGDAHL
1
;
Jane Dahl ANDERSEN
Author Information
1. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. bente.langdahl@aarhus.rm.dk
- Publication Type:Review
- Keywords:
Abaloparatide;
Fracture;
Osteoporosis;
Romozosumab;
Teriparatide
- MeSH:
Bone Density;
Humans;
Osteoporosis*;
Teriparatide
- From:Journal of Bone Metabolism
2018;25(3):133-140
- CountryRepublic of Korea
- Language:English
-
Abstract:
Efficient therapies are available for the treatment of osteoporosis, however, there are still unmet needs. Anti-resorptive therapies only increase bone mineral density to a certain extent and reduce the risk of non-vertebral fractures by 20%, only one anabolic option is available in most parts of the world-the effect of which levels off over time, and the evidence for combination therapy targeting both resorption and formation is limited. In addition, identification and treatment of patients with high and imminent fracture risk following a recent fracture and long-term adherence to treatment are 2 other very prominent challenges to the management of osteoporosis. The current review will focus on emerging osteoporosis treatments and optimized use of the existing treatments that may help overcome the currently unmet needs in the management of osteoporosis.
